Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate (ADC) sac-TMT already
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
ASCO: Revolution Medicines confident in RAS leadership as rivals square up
The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth…
An experimental antibody-drug conjugate from Merck and Kelun-Biotech succeeded in a global Phase 3 study for the first time,…
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
